• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Galapagos NV ADR (NQ: GLPG )

    28.85 -0.42 (-1.43%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 93,469
    Open 29.31
    Bid (Size) 28.10 (1)
    Ask (Size) 29.74 (1)
    Prev. Close 29.27
    Today's Range 28.78 - 29.42
    52wk Range 24.16 - 42.45
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'
    Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees shares as deeply undervalued despite challenges, with new focus on CAR-T... 
    Via Benzinga

    Performance

    YTD
    -30.21%
    -30.21%
    1 Month
    +1.62%
    +1.62%
    3 Month
    +10.20%
    +10.20%
    6 Month
    -11.72%
    -11.72%
    1 Year
    -16.88%
    -16.88%

    More News

    Read More
    Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
    Via Investor's Business Daily
    Exposures Product Safety
    Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    8 Analysts Have This to Say About Galapagos
    Via Benzinga
    Where Galapagos Stands With Analysts
    Via Benzinga
    JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know
    Via Benzinga
    Earnings Outlook For Galapagos
    Via Benzinga
    Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
    Via Benzinga
    Exposures Product Safety
    GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
    Via Newsfile
    Earnings Preview For Galapagos
    Via Benzinga
    Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
    Via Benzinga
    Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
    From Frontier Medicines
    Via GlobeNewswire
    European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
    Via Benzinga
    GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
    Via Benzinga
    BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients
    Via Benzinga
    Why Galapagos Stock Is Falling Today
    Via Benzinga
    Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
    Via Benzinga
    On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.